Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Nutritional and Metabolic Diseases

Rare Diseases

Lung Neoplasms

Lung Diseases

Lung Diseases, Obstructive

Pulmonary Disease, Chronic Obstructive

Calcinosis

Undiagnosed Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Respiratory Tract Diseases

Metabolic Diseases

Calcium Metabolism Disorders

Chronic Graft Versus Host Disease

Lipid Regulating Agents

All Drugs and Chemicals

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy.

Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images

Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy.

CAC score obtained from lung cancer screening CT Scan images

Patients with untreated COPD or not on first line guideline recommended therapy.

Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.

Educational material and treatment recommendations for patients, general practitioners and pharmacists

Nicole Ezer, MD

Nicole Ezer, MD MPH

Charlotte Besson, PHD

Emily McDonald, MD MSc

Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months

Quebec Lung Cancer Screening PLUS Trial

Quebec Lung Cancer Screening PLUS Trial - a Randomized Controlled Trial of an Educational Intervention for Untreated Chronic Obstructive Pulmonary Disease (COPD) and/or Cardiovascular Disease (CVD) Identified During Lung Cancer Screening

Among patients with moderate to severe coronary artery calcifications (CAC) not on a statin at baseline, any statin prescribed for primary prevention at least once in the 1 year following the first low dose CT scan.

(aim 1)

Among patients who have untreated or inappropriately treated COPD at baseline, any long acting muscarinic antagonist inhaler prescribed at least once in the 1 year following the first low dose CT scan (aim 2)

Reflects patient adherence. Days of drug supply over 1 year with cholesterol lowering medication in the previous 1 year from pharmacy dispensation records.

Reflects patient adherence. Days of drug supply over 1 year with guideline concordant inhaler therapy for COPD in the previous 1 year from pharmacy dispensation records.

COPD Assessment Test is a validated patient-reported outcome. It measures 8 symptoms of COPD on a 0-5 point scale at baseline, 6 and 12 months post intervention

SF-36 questionnaire will be filled at baseline and 12 months post intervention

COMRADE is a 20-item self-reported measure for use in primary care to assess risk communication and confidence in treatment decision making. It assesses patient satisfaction with information provided about risks/benefits of treatment, perception of participation in treatment decisions, and satisfaction with that decision.

COMRADE questionnaire will be sent to patients after their first meeting with their general practitioner up to 3 months after intervention.

Number of unplanned clinic visits, hospitalizations for respiratory or cardiac disease, consultations with specialists (cardiology and respirology), invasive/non-invasive cardiac or respiratory investigations

Work productivity and activity impairment (WPAI) questionnaire

Health literacy will be assessed at study entry using the Brief Health Literacy Screen.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Quebec Lung Cancer Screening PLUS Trial	NCT05444062	COPD Coronary Artery...	Educational mat...	55 Years - 74 Years	McGill University Health Centre/Research Institute of the McGill University Health Centre
Quebec Lung Cancer Screening PLUS Trial	NCT05444062	COPD Coronary Artery...	Educational mat...	55 Years - 74 Years	McGill University Health Centre/Research Institute of the McGill University Health Centre

Spots Global Cancer Trial Database for educational material and treatment recommendations for patients, general practitioners and pharmacists